Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Network Meta-Analysis Evaluates Seven Herbal Injections for Acute Ischemic Stroke

4 hours ago 6

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

A comprehensive network meta-analysis evaluating sixty randomized controlled trials has mapped the comparative clinical performance of seven traditional Chinese herbal injections administered alongside conventional Western medicine during the acute phase of ischemic stroke. Published in Frontiers in Pharmacology by a research team based at Changchun University of Chinese Medicine and Jiangxi University of Chinese Medicine, the systematic evaluation compiled data from 6,495 enrolled stroke patients across eight electronic medical databases. The investigators examined pooled clinical outcomes across multiple therapeutic dimensions, discovering that Shuxuening injection combined with conventional Western therapy achieved the highest surface under the cumulative ranking curve probability for overall clinical effective rate, hemodynamic reduction, and systemic tumor necrosis factor-alpha lowering. Simultaneously, the quantitative synthesis revealed distinct outcome-specific advantages across different formulations, finding that Honghua injection combined with standard care demonstrated the greatest relative benefit in reducing neurological deficit scores, while Safflower Yellow injection produced the most pronounced improvements in everyday living abilities.

Acute ischemic stroke, which accounts for roughly eighty-seven percent of all recorded stroke cases globally, arises from sudden cerebral vascular occlusion that precipitates focal ischemia, hypoxia, and permanent neurological dysfunction. Standard emergency interventions center on ultra-early vascular recanalization through intravenous recombinant tissue plasminogen activator thrombolysis or endovascular thrombectomy, both intended to re-establish blood flow to the metabolically vulnerable ischemic penumbra. However, rigid therapeutic time windows and stringent eligibility criteria restrict intravenous thrombolysis to fewer than five percent of presenting patients, while invasive recanalization procedures frequently induce secondary ischemia-reperfusion injuries characterized by neurovascular inflammation, blood-brain barrier breakdown, and microvascular edema. Consequently, conservative medical management remains the primary clinical path for a broad demographic of patients who present beyond standard time thresholds, possess explicit contraindications to thrombolytic agents, or experience mild deficits. In clinical practice across China, blood-activating herbal injections are widely prescribed alongside baseline pharmaceutical care, yet therapeutic choices have historically relied on regional empirical conventions rather than rigorous head-to-head comparative assessments.

To establish systematic comparative hierarchies among these adjunctive therapies, the authors registered their protocol in the International Prospective Register of Systematic Reviews under registration CRD42024506917 and conducted literature searches spanning the inception of eight biomedical databases through March 2026. The search retrieved 4,326 initial records across PubMed, Embase, the Cochrane Library, Web of Science, and four major Chinese academic databases. Following rigorous tiered screening against established criteria for Preferred Reporting Items for Systematic Reviews and Meta-Analyses, sixty parallel-group randomized controlled trials met all inclusion benchmarks. Eligible studies enrolled adult patients within fourteen days of ischemic stroke symptom onset and evaluated one of seven standardized Chinese medicine injections paired with domestic guideline-directed conventional Western medical interventions. Trials assessing surgical recanalization, acupuncture, multi-herbal decoctions, non-standardized formulations, or treatments initiated beyond the two-week acute window were systematically excluded to preserve demographic, clinical, and methodological transitivity across the evidence network.

The investigated herbal formulations comprised Shuxuening injection derived from Ginkgo biloba leaves, Danshen injection prepared from Salvia miltiorrhiza roots, Honghua injection from Carthamus tinctorius flowers, Xuesaitong injection formulated from Panax notoginseng saponins, Ginkgo Diterpene Lactone Meglumine injection containing isolated ginkgo lactones, Safflower Yellow injection isolating water-soluble pigments from Carthamus tinctorius, and Salvianolic Acid injection enriched for phenolic compounds from Salvia miltiorrhiza. In the synthesized trial population, 3,254 participants received an herbal injection combined with conventional medical therapy, while 3,241 participants served in control cohorts receiving either identical conventional Western medicine alone or an alternative active comparator from the seven defined herbal combinations. Standardized background Western medical care consistently comprised guideline-recommended antiplatelet medications, statins for plaque stabilization, circulation-improving pharmaceuticals, neuroprotective agents, and free-radical scavenging antioxidants, establishing an equivalent physiological baseline across arms to minimize confounding co-intervention effects.

Methodological quality across the sixty trials was evaluated using version 5.4.1 of the Cochrane Risk of Bias tool by two independent researchers, with consensus arbitration by a third reviewer. While all included trials claimed random allocation, only twenty-four publications explicitly described sequence generation using random number tables, earning low-risk ratings in that specific domain. Crucially, none of the included studies provided sufficient documentation regarding allocation concealment, and none reported blinding protocols for participants, healthcare practitioners, or outcome assessors, resulting in unclear risk-of-bias ratings across performance and detection domains. Completeness of outcome reporting was consistently verified across all papers without evidence of selective publication anomalies within individual trial reports. The subsequent certainty of evidence was appraised through the Grading of Recommendations Assessment, Development and Evaluation framework, which assigned moderate certainty ratings across key clinical outcomes, primarily downgrading confidence due to persistent ambiguities in trial execution details.

Quantitative network modeling was executed within Stata 17.0 utilizing a frequentist random-effects framework, with continuous metrics synthesized via standardized mean differences and dichotomous variables assessed via risk ratios, accompanied by ninety-five percent confidence intervals. For the primary outcome of overall clinical effective rate, synthesized from forty-three trials, the cumulative probability ranking identified Shuxuening plus Western medicine as the most effective regimen, followed sequentially by Honghua, Safflower Yellow, Salvianolic Acid, Xuesaitong, Ginkgo Diterpene Lactone Meglumine, Danshen, and control Western therapy alone. Pairwise network comparisons demonstrated statistically significant advantages for Shuxuening plus Western medicine over both Danshen plus standard care and standard care alone. Additional significant superiorities over standard care were established for regimens incorporating Safflower Yellow, Xuesaitong, and Ginkgo Diterpene Lactone Meglumine, confirming that specific adjunctive injections enhanced overall clinical response frequencies beyond standard pharmaceutical therapy.

Neurological deficit recovery, assessed using the National Institutes of Health Stroke Scale across forty-eight trials, demonstrated a contrasting therapeutic hierarchy. Honghua injection combined with Western medicine achieved the premier cumulative ranking position, followed by Safflower Yellow, Ginkgo Diterpene Lactone Meglumine, Danshen, Shuxuening, Xuesaitong, Salvianolic Acid, and control Western care alone. Direct and indirect comparisons confirmed that Honghua combined with Western medicine significantly outperformed Shuxuening, Salvianolic Acid, Xuesaitong, Ginkgo Diterpene Lactone Meglumine, and control therapy in lowering deficit scores. Safflower Yellow combinations similarly displayed statistically significant improvements over Shuxuening, Xuesaitong, and isolated Western therapy. These findings underscore that general overall response rates do not uniformly reflect specific neurological functional gains, illustrating how particular flavonoid and safflower yellow pigment extracts might exert preferential protection on infarcted brain tissue and motor pathway restoration.

The evaluation of blood rheology and inflammatory mediators highlighted further divergent biochemical profiles among the preparations. For hemorheological parameters, synthesized across fifteen trials reporting plasma viscosity and thirteen trials examining low and high shear whole blood viscosity, Shuxuening combined with Western medicine consistently occupied the top ranking for viscosity reduction, showing statistically significant decreases in low shear viscosity compared against both Xuesaitong combinations and conventional therapy alone. In contrast, systemic inflammatory markers displayed distinct leaders: Xuesaitong plus Western medicine proved optimal for lowering C-reactive protein concentrations across fifteen trials, significantly exceeding conventional medical treatment alone. For tumor necrosis factor-alpha reduction across nine trials, Shuxuening combined with standard therapy demonstrated the strongest depressive effect, achieving statistically significant superiority over isolated Western care. In activities of daily living across twenty-three trials, Safflower Yellow injection emerged as the highest-ranked intervention, showing significant pairwise improvements over Shuxuening and standard Western management.

Safety outcomes were captured in only seven of the sixty reviewed clinical trials, representing a small subpopulation of 698 patients divided equally between experimental and control arms. Across the monitored cohorts, recorded adverse reactions were predominantly mild and resolved without irreversible sequelae. Reported events in Xuesaitong groups included four cases of gastrointestinal discomfort, two instances of headache or dizziness, one dermatological reaction, and one case of transient hepatic function abnormality, which mirrored similar adverse frequencies in corresponding control groups. Salvianolic Acid trials documented four gastrointestinal complaints, two skin reactions, and two hepatic enzyme elevations, while Safflower Yellow was linked to two transient febrile episodes. Ginkgo Diterpene Lactone Meglumine cohorts exhibited five gastrointestinal disturbances and two skin reactions. Notably, the literature lacked standardized long-term pharmacovigilance or systematic tracking of rare, severe events such as cerebral hemorrhage or systemic anaphylaxis, precluding conclusive comparative assessments of safety profiles.

The review authors emphasized several prominent limitations that constrain the immediate translation of these findings into clinical guidelines. All sixty included trials were single-center investigations conducted exclusively within domestic Chinese hospital environments with relatively small sample sizes and brief follow-up intervals ranging from seven to thirty days, providing no data regarding long-term functional recovery or recurrence rates beyond one month. Furthermore, baseline stroke severity, patient age, and comorbid vascular conditions were inconsistently reported across source papers, which likely introduced unmeasured clinical heterogeneity into pooled statistical estimates. Potential publication bias arising from underreported negative trials and the absence of allocation concealment and double-blinding further temper the confidence of the observed rankings. While Shuxuening, Honghua, and Safflower Yellow demonstrated distinct statistical advantages in their respective clinical domains, the authors concluded that these preliminary rankings require validation through multi-center, rigorously blinded clinical trials incorporating comprehensive safety monitoring before specific herbal injections can be definitively recommended for routine stroke management.

Subject of Research: Comparative clinical efficacy and safety of traditional Chinese medicine injections combined with Western medicine for acute ischemic stroke

Article Title: Efficacy and safety of seven traditional Chinese medicine injections combined with western medicine for acute ischemic stroke: a systematic review and network meta-analysis

Article References: Zhang, H., Lin, M., Song, C., Zhao, D., Nan, Z., & Fu, Y. (2026). Efficacy and safety of seven traditional Chinese medicine injections combined with western medicine for acute ischemic stroke: a systematic review and network meta-analysis. Frontiers in Pharmacology, 17, Article 1881071. https://doi.org/10.3389/fphar.2026.1881071

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1881071

Keywords: acute ischemic stroke, network meta-analysis, traditional Chinese medicine, Shuxuening injection, Honghua injection, Xuesaitong injection, Safflower Yellow injection, Salvianolic Acid injection, Ginkgo Diterpene Lactone Meglumine injection, Danshen injection, neurological deficit, National Institutes of Health Stroke Scale, activities of daily living, hemodynamic indicators, systematic review, randomized controlled trials, C-reactive protein, tumor necrosis factor-alpha

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway